Edit |   |
---|---|
Product Name | ABT-199 (Venetoclax) |
Description | Purity >98%. ABT-199 is a so-called BH3-mimetic drug, which is designed to block the function of the protein Bcl 2. MW: 868.44 |
Size | 10 mg, 1 mL (in DMSO), 25 mg |
Concentration | 0.1 mM: 11.51 mL (1 mg); 57.57 mL (5 mg); 115.15mL (10 mg). 0.5 mM: 2.3 mL (1 mg); 11.51 mL (5 mg); 23.03 mL (10 mg). 1 mM: 1.15 mL (1 mg); 5.76 mL (5 mg); 11.51 mL (10 mg). 5 mM: 0.23 mL (1 mg); 1.15 mL (5 mg); 2.3 mL (10 mg) |
Applications | n/a |
Other Names | n/a |
Gene, Accession, CAS # | CAS: 1257044-40-8 |
Catalog # | MBS384107 |
Price | $180, $225, $310 |
Order / More Info | ABT-199 (Venetoclax) from MYBIOSOURCE INC. |
Product Specific References | Chauhan D,.et al. BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1 Maturation in Macrophages, Cell Rep, 2018, Nov 27;25(9):2354-2368.e5 PMID: 30485805Martin Grundy,.et al. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling, PLoS One, 2018, 13(1): e0190682 PMID: 29298347Joanne Dai,.et al. Intracellular BH3 profiling reveals shifts in anti-apoptotic dependency in B-cell maturation and activation, J Immunol, 2018, 200 (5) 1727-1736 PMID: 29358277 |